Literature DB >> 7845532

Transferrin receptors in the parkinsonian midbrain.

C M Morris1, J M Candy, S Omar, C A Bloxham, J A Edwardson.   

Abstract

Several hypotheses have been put forward to explain the pathogenesis of Parkinson's disease (PD) and recently it has been suggested that alterations in iron homeostasis may be implicated. Because of the central role of the transferrin receptor in providing access of iron to cells, we have studied the distribution and density of transferrin receptors using [3H]-transferrin ([3H]-Tf) binding and tritium film autoradiography in the normal and PD midbrain. High levels of [3H]-Tf binding were found in the dorsal raphé, oculomotor nucleus and periaqueductal grey whilst lower levels of [3H]-Tf binding were found in the tegmentum, red nucleus and substantia nigra. Significant reductions in binding were found in the substantia nigra, red nucleus and oculomotor nucleus in PD, the reductions in [3H]-Tf binding being similar to the loss of nigral neurons in PD. The data suggest that the increased iron content of surviving nigral neurons may reflect a compensatory metabolic response rather than abnormal transferrin receptor expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7845532     DOI: 10.1111/j.1365-2990.1994.tb00997.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  15 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Imaging chronic daily headache.

Authors:  Sheena K Aurora
Journal:  Curr Pain Headache Rep       Date:  2003-06

3.  Bayesian inference for parameter estimation in lactoferrin-mediated iron transport across blood-brain barrier.

Authors:  Aminul Islam Khan; Jin Liu; Prashanta Dutta
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-11-01       Impact factor: 3.770

4.  Hypercapnia causes cellular oxidation and nitrosation in addition to acidosis: implications for CO2 chemoreceptor function and dysfunction.

Authors:  Jay B Dean
Journal:  J Appl Physiol (1985)       Date:  2010-02-11

5.  Cp/Heph mutant mice have iron-induced neurodegeneration diminished by deferiprone.

Authors:  Liangliang Zhao; Majda Hadziahmetovic; Chenguang Wang; Xueying Xu; Ying Song; H A Jinnah; Jolanta Wodzinska; Jared Iacovelli; Natalie Wolkow; Predrag Krajacic; Alyssa Cwanger Weissberger; John Connelly; Michael Spino; Michael K Lee; James Connor; Benoit Giasson; Z Leah Harris; Joshua L Dunaief
Journal:  J Neurochem       Date:  2015-09-29       Impact factor: 5.372

6.  Effects of gender on nigral gene expression and parkinson disease.

Authors:  Ippolita Cantuti-Castelvetri; Christine Keller-McGandy; Bérengère Bouzou; Georgios Asteris; Timothy W Clark; Matthew P Frosch; David G Standaert
Journal:  Neurobiol Dis       Date:  2007-03-03       Impact factor: 5.996

7.  Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.

Authors:  B A Faucheux; N Nillesse; P Damier; G Spik; A Mouatt-Prigent; A Pierce; B Leveugle; N Kubis; J J Hauw; Y Agid
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

8.  Parkinson's disease iron deposition caused by nitric oxide-induced loss of β-amyloid precursor protein.

Authors:  Scott Ayton; Peng Lei; Dominic J Hare; James A Duce; Jessica L George; Paul A Adlard; Catriona McLean; Jack T Rogers; Robert A Cherny; David I Finkelstein; Ashley I Bush
Journal:  J Neurosci       Date:  2015-02-25       Impact factor: 6.167

9.  Chelators in the treatment of iron accumulation in Parkinson's disease.

Authors:  Ross B Mounsey; Peter Teismann
Journal:  Int J Cell Biol       Date:  2012-06-13

Review 10.  Targeting iron metabolism in drug discovery and delivery.

Authors:  Bart J Crielaard; Twan Lammers; Stefano Rivella
Journal:  Nat Rev Drug Discov       Date:  2017-02-03       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.